Edwards Lifesciences reported strong financial results for the second quarter ended June 30, 2025, with total company sales reaching $1.53 billion, an increase of 8.9% (7.8% constant currency) over the prior year. This performance was driven by better-than-expected growth across its core businesses.
Transcatheter Aortic Valve Replacement (TAVR) sales were $1.1 billion, up 8.9% (7.8% constant currency), benefiting from continued clinician adoption of SAPIEN technology. Transcatheter Mitral and Tricuspid Therapies (TMTT) sales surged to $134.5 million, growing 61.9% (57.1% adjusted), with strong adoption of PASCAL and EVOQUE. Surgical sales increased 7.7% (6.8% constant currency) to $267 million.
The company raised its full-year total company sales growth guidance to 9% to 10%, with sales projected between $5.9 billion and $6.1 billion. TAVR underlying growth guidance was increased to 6% to 7%, with sales of $4.3 billion to $4.5 billion. Edwards also raised its full-year adjusted EPS guidance to the high end of its original range of $2.40 to $2.50, reflecting confidence in its portfolio and operational execution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.